Medifast, Inc.

NYSE:MED

Personal Products & Services

Consumer Cyclical
$12.20 -0.04%

-$0.01 today

Market cap
$136.43M
Beta
0.66
P/E (TTM)
-6.2
EPS (TTM)
-$1.82
52W Low $9.22High $15.46

Volume 0.09M

Average 0.21M

MED EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Medifast, Inc.NYSE: MED

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA dips below year-ago levels

Q1 FY2026 EBITDA of $1.54M fell 59.5% year over year, behind the +16.2% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at -70.8% a year.

Context

  • EBITDA amounted to 1.3% of revenue in FY2025, down 1.5 pp from a year earlier.
  • EBITDA increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $2.71M (-44.3%) for the fiscal year ending Dec 2026, a step up from the -70.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.54M+152.9% QoQ
Last fiscal yearDec 2025
$4.86M-70.5% YoY
LTMMar 2026
$6.34M+16.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.5%-155.2%-95.7 pp
1 year-70.5%-44.3%+26.3 pp
3-year CAGR-70.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
4.86M USD
Year-over-year change
-70.5%
4-year CAGR
-61.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MED compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.2% is the 4th highest of 10, against a peer median of +6.2%.
  • EBITDA amounts to 1.8% of revenue for MED, versus a peer median of 7.4%.
MED Competitors
EBITDA for MED and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAASChina Automotive Systems, Inc.LTM Dec 2025$71.37M USD+7.9%+15.9%9.3%
CURVTorrid Holdings Inc.LTM May 2026$61.91M USD-50.3%-20.5%6.3%
MBMasterBeef GroupFY2025HK$30.75M HKD-75.3%-35.4%6.7%
KEQUKewaunee Scientific CorporationLTM Jan 2026$26.69M USD+75.6%+191.8%9.3%
BSETBassett Furniture Industries, IncorporatedLTM Feb 2026$17.97M USD+24851.4%-26.4%5.4%
MEDMedifast, Inc.LTM Mar 2026$6.34M USD+16.2%-70.8%1.8%
AKAa.k.a. Brands Holding Corp.LTM Mar 2026-$296K USD-104.1%—0.0%
DIBS1stdibs.Com, Inc.LTM Mar 2026-$6.58M USD+25.2%—7.4%
CLARClarus CorporationLTM Mar 2026-$41.72M USD-325.6%—16.5%
AIIORobo.ai Inc.FY2025-$156.14M USD+6.2%—16436.0%
Peer median (excluding MED) —+6.2%-20.5%7.4%

Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.53B1.6B1.07B602.46M385.79M
Cost of Revenue398.49M458.16M296.2M157.84M110.6M
Gross Profit1.13B1.14B775.85M444.62M275.19M
Gross Margin73.9%71.3%72.4%73.8%71.3%
Research & Development00000
Selling, General & Admin911.36M955.61M649.45M441.75M289.4M
Operating Expenses911.36M955.61M649.45M441.75M289.4M
Depreciation & Amortization6.81M10.98M13.11M12.71M10.5M
EBITDA222.94M195.74M141.9M16.49M4.86M
EBITDA Margin14.6%12.2%13.2%2.7%1.3%
Operating Income216.24M184.81M126.4M2.88M(14.21M)
Operating Margin14.2%11.6%11.8%0.5%-3.7%
Interest Income002.49M4.8M5.52M
Interest Expense231K701K000
Other Income / Expenses(112K)(747K)2.4M909K8.57M
Income Before Tax216.13M184.06M128.8M3.79M(5.64M)
Pre-Tax Margin14.2%11.5%12.0%0.6%-1.5%
Income Tax Expense52.1M40.49M29.38M1.7M13.03M
Net Income164.03M143.57M99.42M2.09M(18.67M)
Net Margin10.7%9.0%9.3%0.3%-4.8%
EPS (Basic)14.0112.829.100.19(1.70)
EPS (Diluted)13.8912.739.100.19(1.70)
Weighted Avg Shares11.71M11.2M10.88M10.93M10.98M
Weighted Avg Shares (Diluted)11.81M11.28M10.92M10.96M10.98M

Medifast, Inc.

NYSE:MED

Intrinsic Alpha fair value

Locked

Current Price

$12.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.